Abstract

Despite the large investments made in drug discovery in the past decade, there is still a dearth of new drugs. This highlights the persistence of a model of drug development that has not adapted to changes in science, public perception of drug companies or the marketplace. A high profit margin in the United States has shielded drug development from the usual economic pressures that would ordinarily drive reform. The strategy of merger, pursued by many companies to compensate for the failure to develop new drugs, has, in most cases, compounded the problem, imposing geographic and cultural segregation on an already inefficient process.

Author affiliations

1. Garret A. FitzGerald is at The Institute for Translational Medicine and Therapeutics, Room 805, Biomedical Research Building 2/3, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
   Email: garret@spirit.gcrc.upenn.edu

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.